Amneal Pharmaceuticals Securities Litigation Settlement
This settlement is closed to new claims. You can still see what it was about and follow the case in court below. Looking for money you can still claim? Browse open settlements →
What happened
Amneal Pharmaceuticals and certain officers and directors allegedly violated the Securities Act of 1933 by making false and misleading statements and omissions in registration statements and prospectus for Amneal common stock issued in connection with the business combination of Legacy Amneal and Impax Laboratories. The defendants settled for $25 million without admitting wrongdoing.
Do you qualify?
Anyone who purchased or otherwise acquired publicly traded Class A common stock of Amneal issued in connection with the business combination between Legacy Amneal and Impax during May 7, 2018 through May 5, 2021, and was damaged thereby. Excluded are defendants, officers, directors, and affiliates of the companies involved.
How to file
The claims administration was completed in April 2024. Eligible claimants have already been approved and initial distributions were made in July 2024 with a second distribution in July 2025. For more information, contact the Claims Administrator at 866-615-0973 or info@AmnealSecuritiesLitigation.com.
Common questions
- How much does the Amneal Pharmaceuticals Securities Litigation Settlement pay?
- The total settlement fund is $25M. Actual amounts depend on how many valid claims are filed — most settlements divide a fixed fund pro rata, so a higher claim rate means a smaller individual check. An "up to" figure is a cap, not a guarantee.
- Is the Amneal Pharmaceuticals Securities Litigation Settlement notice real, or a scam?
- JND Legal Administration is the settlement administrator for this case. Claims are filed at amnealsecuritieslitigation.com. Filing a class action claim is always free — no legitimate settlement charges you to claim, and no administrator will ask for payment, a gift card, or your full Social Security number by email or text. If a notice asks for any of those, it is not from the administrator. When in doubt, ignore the link you were sent and go to the official settlement website directly.
- When will payments from the Amneal Pharmaceuticals Securities Litigation Settlement be sent?
- Class action payouts typically take 12 to 24 months after the claim deadline, and longer if the settlement is appealed. The final approval hearing for this case is set for August 15, 2022; no payments can be issued before a settlement receives final approval.
New to class actions?
This summary was generated from public settlement documents and may contain errors. Confirm eligibility, deadlines, and payment terms on the official settlement website before filing. ClaimWatch is not a law firm and this is not legal advice. Filing a claim is free.
More securities settlements
View all →Revance Securities Settlement
Revance Therapeutics and its executives made material misrepresentations and omissions regarding the company's relationship with Teoxane SA and the tender offer and merger transaction with Crown Laboratories, Inc., allegedly violating federal securities laws. Defendants deny any wrongdoing or liability.
Not yet determinable; depends on number of valid claims submitted
Biogen Securities Litigation Settlement
Biogen Inc. investors have settled a securities litigation case for $18.9 million in cash. The settlement resolves claims related to purchases of Biogen common stock during the specified class period.
NJ Bureau of Securities Settlement with Credit Suisse
Credit Suisse allegedly violated New Jersey Securities Law by making materially false and misleading statements regarding RMBS trust certificates and engaging in fraudulent practices. On October 24, 2022, the court entered a consent order requiring Credit Suisse to pay $300 million in restitution to investors. Credit Suisse neither admitted nor denied the allegations.
Stitch Fix Securities Litigation Settlement
Stitch Fix, Inc. is settling a securities class action lawsuit without admitting wrongdoing. The Lead Plaintiffs alleged that Stitch Fix issued misleading statements about its business, and shareholders who purchased the stock during the class period suffered damages as a result.